S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

William Blair Brokers Reduce Earnings Estimates for MaxCyte, Inc. (NASDAQ:MXCT)

Last updated on Saturday, May 14, 2022 | 2022 MarketBeat

MaxCyte, Inc. (NASDAQ:MXCT - Get Rating) - Stock analysts at William Blair decreased their Q2 2022 EPS estimates for MaxCyte in a report released on Tuesday, May 10th. William Blair analyst M. Larew now expects that the company will post earnings per share of ($0.09) for the quarter, down from their previous forecast of ($0.07). William Blair also issued estimates for MaxCyte's Q3 2022 earnings at ($0.10) EPS, Q4 2022 earnings at ($0.06) EPS, FY2022 earnings at ($0.29) EPS and FY2023 earnings at ($0.27) EPS. MaxCyte (NASDAQ:MXCT - Get Rating) last issued its quarterly earnings data on Tuesday, March 22nd. The company reported ($0.05) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.05). MaxCyte had a negative return on equity of 7.39% and a negative net margin of 41.15%.

Shares of MXCT stock opened at $4.40 on Thursday. The company has a market capitalization of $446.78 million and a P/E ratio of -25.88. The company's 50-day moving average is $5.89. MaxCyte has a 1-year low of $4.00 and a 1-year high of $17.44.

Hedge funds and other institutional investors have recently modified their holdings of the business. Freemont Management S.A. acquired a new stake in MaxCyte in the first quarter worth about $68,000. Nkcfo LLC acquired a new stake in MaxCyte in the first quarter worth about $91,000. Strs Ohio boosted its holdings in MaxCyte by 588.9% in the first quarter. Strs Ohio now owns 24,800 shares of the company's stock worth $173,000 after acquiring an additional 21,200 shares in the last quarter. ProShare Advisors LLC acquired a new stake in MaxCyte in the first quarter worth about $204,000. Finally, Qube Research & Technologies Ltd acquired a new stake in MaxCyte in the first quarter worth about $280,000. 65.86% of the stock is owned by institutional investors and hedge funds.

MaxCyte Company Profile (Get Rating)

MaxCyte, Inc, a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in MaxCyte right now?

Before you consider MaxCyte, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.

While MaxCyte currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here



Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.